The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma
Lu, Zhihao, Yang, Silu, Luo, Xuerui, Shi, Yang, Lee, Jong-Seok, Deva, Sanjeev, Liu, Tianshu, Chao, Yee, Zhang, Yun, Huang, Ruiqi, Xu, Yaling, Shen, Zhirong, Shen, Lin
Published in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (01.09.2022)
Published in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (01.09.2022)
Get full text
Journal Article
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
Desai, Jayesh, Deva, Sanjeev, Lee, Jong Seok, Lin, Chia-Chi, Yen, Chia-Jui, Chao, Yee, Keam, Bhumsuk, Jameson, Michael, Hou, Ming-Mo, Kang, Yoon-Koo, Markman, Ben, Lu, Chang-Hsien, Rau, Kun-Ming, Lee, Kyung-Hun, Horvath, Lisa, Friedlander, Michael, Hill, Andrew, Sandhu, Shahneen, Barlow, Paula, Wu, Chi-Yuan, Zhang, Yun, Liang, Liang, Wu, John, Paton, Virginia, Millward, Michael
Published in Journal for immunotherapy of cancer (01.06.2020)
Published in Journal for immunotherapy of cancer (01.06.2020)
Get full text
Journal Article
Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors
Odegard, Jared M, Othman, Ahmed A, Lin, Kai-Wen, Wang, Adele Y, Nazareno, Jonathan, Yoon, Oh Kyu, Ling, John, Lad, Latesh, Dunbar, P Rod, Thai, Dung, Ang, Edmond, Waldron, Nicholas, Deva, Sanjeev
Published in Journal for immunotherapy of cancer (11.04.2024)
Published in Journal for immunotherapy of cancer (11.04.2024)
Get full text
Journal Article
Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors
He, Jimmy, Jackson, Christopher G. C. A., Deva, Sanjeev, Hung, Tak, Clarke, Katriona, Segelov, Eva, Chao, Tsu‐Yi, Dai, Ming‐Shen, Yeh, Hsien‐Tang, Ma, Wen Wee, Kramer, Douglas, Chan, Wing‐Kai, Kwan, Rudolf, Cutler, David, Zhi, Jay
Published in CPT: pharmacometrics and systems pharmacology (01.07.2022)
Published in CPT: pharmacometrics and systems pharmacology (01.07.2022)
Get full text
Journal Article
76 Potential mechanisms of resistance identified through analysis of multiple biomarkers in immune hot non-responders with non-small cell lung cancer (NSCLC) treated with tislelizumab
Desai, Jayesh, Zhou, Qing, Deva, Sanjeev, Zhao, Jun, Wang, Jie, Tan, Wei, Ma, Xiaopeng, Zhang, Yun, Shen, Zhirong, Wu, Xikun, Leaw, Shiangjiin, Zhang, Juan, Wu, Yi-Long
Published in Journal for immunotherapy of cancer (01.11.2020)
Published in Journal for immunotherapy of cancer (01.11.2020)
Get full text
Journal Article
Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/β-Catenin Signaling in BRAF-mutant Colorectal Cancer Models
Tran, Khanh B, Kolekar, Sharada, Wang, Qian, Shih, Jen-Hsing, Buchanan, Christina M, Deva, Sanjeev, Shepherd, Peter R
Published in Molecular cancer therapeutics (02.12.2022)
Published in Molecular cancer therapeutics (02.12.2022)
Get full text
Journal Article
Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial
Cohen, Ezra E W, Nabell, Lisle, Wong, Deborah J, Day, Terry, Daniels, Gregory A, Milhem, Mohammed, Deva, Sanjeev, Jameson, Michael, Guntinas-Lichius, Orlando, Almubarak, Mohammed, Strother, Matthew, Whitman, Eric, Chisamore, Michael, Obiozor, Cynthia, Bagulho, Teresa, Gomez-Romo, Jose, Guiducci, Cristiana, Janssen, Robert, Gamelin, Erick, Algazi, Alain P
Published in Clinical cancer research (15.03.2022)
Published in Clinical cancer research (15.03.2022)
Get full text
Journal Article
A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors
Desai, Jayesh, Davar, Diwakar, Deva, Sanjeev, Gao, Bo, Liu, Tianshu, Matos, Marco, Meniawy, Tarek, O'Byrne, Kenneth John, Sun, Meili, Voskoboynik, Mark, Yang, Kunyu, Yu, Xinmin, Chen, Xin, Dong, Yan, Giovinazzo, Hugh, Leaw, Shiangjiin, Patel, Deepa, Rahman, Tahmina, Wu, Yanjie, Day, Daphne
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article
Real-world outcomes of cisplatin, capecitabine, and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first-line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma
Hitchen, Nadia, Waldron, Nick R, Deva, Sanjeev, Findlay, Michael, Lawrence, Benjamin
Published in Asia-Pacific journal of clinical oncology (01.10.2023)
Published in Asia-Pacific journal of clinical oncology (01.10.2023)
Get full text
Journal Article
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer
Prenen, Hans, Deva, Sanjeev, Keam, Bhumsuk, Lindsay, Colin R., Lugowska, Iwona, Yang, James C., Longo, Federico, de Miguel, Maria, Ponz-Sarvise, Mariano, Ahn, Myung-Ju, Gumus, Mahmut, Champiat, Stephane, Italiano, Antoine, Salas, Sébastien, Perets, Ruth, Arslan, Cagatay, Cho, Byoung C., Evers, Stefan, Boetsch, Christophe, Marbach, Daniel, Dejardin, David, Sleiman, Nassim, Ardeshir, Caroline, Richard, Muriel, Charo, Jehad, Kraxner, Anton, Keshelava, Nino, Teichgräber, Volker, Moreno, Victor
Published in Clinical cancer research (15.07.2024)
Published in Clinical cancer research (15.07.2024)
Get full text
Journal Article
Immune- and tumor-intrinsic gene expression profiles of response or resistance to tislelizumab as monotherapy or in combination with chemotherapy in non-small cell lung cancer (NSCLC)
Desai, Jayesh, Wang, Jie, Zhou, Qing, Zhao, Jun, Deva, Sanjeev, Tan, Wei, Ma, Xiaopeng, Zhang, Yun, Shen, Zhirong, Wu, Xikun, Leaw, Shiangjiin, Wu, Yanjie, Wu, Yi-Long
Published in Journal of clinical oncology (20.05.2020)
Published in Journal of clinical oncology (20.05.2020)
Get full text
Journal Article
Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic study
Jackson, Christopher G. C. A., Hung, Tak, Segelov, Eva, Barlow, Paula, Prenen, Hans, McLaren, Blair, Hung, Noelyn Anne, Clarke, Katriona, Chao, Tsu‐Yi, Dai, Ming‐Shen, Yeh, Hsien‐Tang, Cutler, David L., Kramer, Douglas, He, Jimmy, Zhi, Jay, Chan, Wing‐Kai, Kwan, Rudolf, Deva, Sanjeev
Published in British journal of clinical pharmacology (01.12.2021)
Published in British journal of clinical pharmacology (01.12.2021)
Get full text
Journal Article
First-line durvalumab + monalizumab, mFOLFOX6, and bevacizumab or cetuximab for metastatic microsatellite-stable colorectal cancer (MSS-CRC)
Wainberg, Zev A., Diamond, Jennifer Robinson, Curigliano, Giuseppe, Deva, Sanjeev, Bendell, Johanna C., Han, Sae-Won, Kalyan, Aparna, Naidoo, Jarushka, Kim, Richard D., Patel, Sandip Pravin, Kourtesis, Panagiotis, Li, Xia, Ascierto, Maria, Song, Xuyang, Das, Mayukh, Segal, Neil Howard
Published in Journal of clinical oncology (01.02.2020)
Published in Journal of clinical oncology (01.02.2020)
Get full text
Journal Article
Comparison of efficacy and tolerability of weekly adjuvant chemotherapy for colorectal cancer (CRC) using folinic acid with fluorouracil dosed at 425 mg/m 2 or 370 mg/m 2
Jameson, Michael B., Lawrence, Nicola Jane, Kennedy, Ian C., Head, Michelle Anne, Deva, Sanjeev
Published in Journal of clinical oncology (20.05.2016)
Published in Journal of clinical oncology (20.05.2016)
Get full text
Journal Article
Abstract CT084: Long-term exposure (LTE) to Tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human Phase I study
Desai, Jayesh, Markman, Benjamin, Friedlander, Michael, Gan, Hui, Horvath, Lisa, Townsend, Amanda, Millward, Michael, Jameson, Michael, Yen, Chia-Jui, Hou, Ming-Mo, Hou, Jeannie, Wu, John, Liang, Liang, Deva, Sanjeev
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Get full text
Journal Article
An open-label, randomized cross-over bioavailability and extension study of oral paclitaxel and HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumours
Jackson, Christopher G. C. A., Deva, Sanjeev, Bayston, Katherine Francis, Eden, Karen, McLaren, Blair Richard, Barlow, Paula, Hung, Noelyn Anne, Clarke, Kate, Cutler, David, Fetterly, Gerald, Kwan, Min-Fun Rudolf, Kramer, Douglas, Chan, Wing Kai, Hung, Tak
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article
Phase 1b/2, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
Cohen, Ezra E.W., Nabell, Lisle, Wong, Deborah J.L., Day, Terry A, Daniels, Gregory A., Milhem, Mohammed M., Deva, Sanjeev, Jameson, Michael B., Guntinas-Lichius, Orlando, Almubarak, Mohammed, Strother, Robert Matthew, Whitman, Eric D., Chisamore, Michael Jon, Obiozor, Cynthia Chinedu, Bagulho, Teresa, Candia, Albert, Gamelin, Erick, Janssen, Robert, Algazi, Alain Patrick
Published in Journal of clinical oncology (20.05.2019)
Published in Journal of clinical oncology (20.05.2019)
Get full text
Journal Article